Doxorubicin concentrations in bone tumour-relevant tissues after bolus and continuous infusion: a randomized porcine microdialysis study.
Bone Cancer
Doxorubicin
Doxorubicinol
Infusion
Microdialysis
Journal
Cancer chemotherapy and pharmacology
ISSN: 1432-0843
Titre abrégé: Cancer Chemother Pharmacol
Pays: Germany
ID NLM: 7806519
Informations de publication
Date de publication:
08 Feb 2024
08 Feb 2024
Historique:
received:
23
09
2023
accepted:
24
12
2023
medline:
9
2
2024
pubmed:
9
2
2024
entrez:
8
2
2024
Statut:
aheadofprint
Résumé
Doxorubicin is a widely used chemotherapeutic drug that can be administered intravenously as both a bolus infusion and a continuous infusion. The latter is believed to lower the risk of cardiotoxicity, which is a critical long-term complication of doxorubicin treatment. The local tissue concentrations of doxorubicin will be reflected in both treatment efficacy and toxicity, but very limited information is available. The aim of this study was to measure the concentration of doxorubicin after continuous and bolus infusion in tissue compartments around a typical location of a bone tumour. Sixteen pigs (female, Danish Landrace, mean weight 77 kg) were randomized into two groups of eight. Both groups received an intravenous infusion of 150 mg doxorubicin; Group 1 received a bolus infusion (10-15 min) and Group 2 received a continuous infusion (6 h). Before infusion, microdialysis catheters were placed intravenously and in four bone tumour-relevant tissue compartments (cancellous bone, subcutaneous tissue, synovial fluid of the knee joint and muscle tissue). Sampling was done (n = 15) over 24 h, and venous blood samples were collected as a reference. Area under the concentration-time curve (AUC The pharmacokinetic profile for doxorubicin in the investigated tissues is very similar when comparing bolus and 6 h continuous infusion.
Identifiants
pubmed: 38332155
doi: 10.1007/s00280-023-04637-1
pii: 10.1007/s00280-023-04637-1
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Novo Nordisk Fonden
ID : NNF19OC0058501
Informations de copyright
© 2024. The Author(s).
Références
Lægemiddelstyrelsen, PRODUKTRESUMÉ for Doxorubicin ”Actavis”, koncentrat til infusionsvæske, opløsning. 12.09.2022: http://produktresume.dk/AppBuilder/search?utf8=✓&id=&type=&q=doxorubicin&button=Søg .
Blum RH, Carter SK (1974) Adriamycin. A new anticancer drug with significant clinical activity. Ann Intern Med 80(2): 249–59
Nicoletto RE, Ofner CM 3rd (2022) Cytotoxic mechanisms of doxorubicin at clinically relevant concentrations in breast cancer cells. Cancer Chemother Pharmacol 89(3):285–311
doi: 10.1007/s00280-022-04400-y
pubmed: 35150291
Minotti G et al (2004) Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56(2):185–229
doi: 10.1124/pr.56.2.6
pubmed: 15169927
Yang F et al (2014) Doxorubicin, DNA torsion, and chromatin dynamics. Biochim Biophys Acta 1845(1):84–89
pubmed: 24361676
Mordente A et al (2009) New developments in anthracycline-induced cardiotoxicity. Curr Med Chem 16(13):1656–1672
doi: 10.2174/092986709788186228
pubmed: 19442138
Legha SS et al (1982) Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 96(2):133–139
doi: 10.7326/0003-4819-96-2-133
pubmed: 7059060
van Dalen EC, van der Pal HJ, Kremer LC (2016) Different dosage schedules for reducing cardiotoxicity in people with cancer receiving anthracycline chemotherapy. Cochrane Database Syst Rev 3(3): Cd005008
Jacquet JM et al (1990) Doxorubicin and doxorubicinol: intra- and inter-individual variations of pharmacokinetic parameters. Cancer Chemother Pharmacol 27(3):219–225
doi: 10.1007/BF00685716
pubmed: 2265458
Piscitelli SC et al (1993) Pharmacokinetics and pharmacodynamics of doxorubicin in patients with small cell lung cancer. Clin Pharmacol Ther 53(5):555–561
doi: 10.1038/clpt.1993.69
pubmed: 8387903
Barpe DR, Rosa DD, Froehlich PE (2010) Pharmacokinetic evaluation of doxorubicin plasma levels in normal and overweight patients with breast cancer and simulation of dose adjustment by different indexes of body mass. Eur J Pharm Sci 41(3–4):458–463
doi: 10.1016/j.ejps.2010.07.015
pubmed: 20688160
O’Bryan RM et al (1977) Dose response evaluation of adriamycin in human neoplasia. Cancer 39(5):1940–1948
doi: 10.1002/1097-0142(197705)39:5<1940::AID-CNCR2820390505>3.0.CO;2-0
pubmed: 858124
Tukenova M et al (2010) Role of cancer treatment in long-term overall and cardiovascular mortality after childhood cancer. J Clin Oncol 28(8):1308–1315
doi: 10.1200/JCO.2008.20.2267
pubmed: 20142603
Robert J (2007) Preclinical assessment of anthracycline cardiotoxicity in laboratory animals: predictiveness and pitfalls. Cell Biol Toxicol 23(1):27–37
doi: 10.1007/s10565-006-0142-9
pubmed: 17041747
Kho CM et al (2017) A review on microdialysis calibration methods: the theory and current related efforts. Mol Neurobiol 54(5):3506–3527
doi: 10.1007/s12035-016-9929-8
pubmed: 27189617
Chaurasia CS et al (2007) AAPS-FDA workshop white paper: microdialysis principles, application and regulatory perspectives. Pharm Res 24(5):1014–1025
doi: 10.1007/s11095-006-9206-z
pubmed: 17458685
Shippenberg TS, Thompson AC (2001) Overview of microdialysis. Curr Protoc Neurosci Chapter 7: Unit7.1
Jørgensen AR et al (2024) Microdialysis as a sampling tool for the chemotherapeutic agent Doxorubicin. J Pharm Biomed Anal 239:115872
doi: 10.1016/j.jpba.2023.115872
pubmed: 38039870
Swindle MM et al (2012) Swine as models in biomedical research and toxicology testing. Vet Pathol 49(2):344–356
doi: 10.1177/0300985811402846
pubmed: 21441112
Bollen PJAea. The Laboratory Swine [cited 2022 09.09]. Available from https://books.google.dk/books?id=TU3RBQAAQBAJ&printsec=frontcover&hl=da#v=onepage&q=body&f=false
Genomics of drug sensitivity in cancer [cited 2022 10.06.22]. Available from https://www.cancerrxgene.org/compound/Doxorubicin/133/overview/ic50 ?
Genomics of Drug Sensitivity in Cancer [cited 2023 20.06]. Available from https://www.cancerrxgene.org/compound/Doxorubicin/133/overview/ic50 ?
Eichholtz-Wirth H (1980) Dependence of the cytostatic effect of adriamycin on drug concentration and exposure time in vitro. Br J Cancer 41(6):886–891
doi: 10.1038/bjc.1980.165
pubmed: 7426313
pmcid: 2010346
Haskell CM, Sullivan A (1974) Comparative survival in tissue culture of normal and neoplastic human cells exposed to adriamycin. Cancer Res 34(11):2991–2994
pubmed: 4417828
Cusack BJ et al (1993) Doxorubicin and doxorubicinol pharmacokinetics and tissue concentrations following bolus injection and continuous infusion of doxorubicin in the rabbit. Cancer Chemother Pharmacol 32(1):53–58
doi: 10.1007/BF00685876
pubmed: 8462124
Brenner DE et al (1984) Human plasma pharmacokinetics of doxorubicin: comparison of bolus and infusional administration. Cancer Treatment Symposia 3:77–83
Lipshultz SE et al (2002) Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91-01 acute lymphoblastic leukemia protocol. J Clin Oncol 20(6):1677–1682
doi: 10.1200/JCO.2002.20.6.1677
pubmed: 11896119
Lipshultz SE et al (2012) Continuous versus bolus infusion of doxorubicin in children with all: long-term cardiac outcomes. Pediatrics 130(6):1003–1011
doi: 10.1542/peds.2012-0727
pubmed: 23166343
pmcid: 3507254
Besse HC, et al (2019) Tumor drug distribution after local drug delivery by hyperthermia, in vivo. Cancers (Basel) 11(10)
Sun M et al (2015) A tissue-engineered therapeutic device inhibits tumor growth in vitro and in vivo. Acta Biomater 18:21–29
doi: 10.1016/j.actbio.2015.02.004
pubmed: 25686557
Cao D et al (2019) Liposomal doxorubicin loaded PLGA-PEG-PLGA based thermogel for sustained local drug delivery for the treatment of breast cancer. Artif Cells Nanomed Biotechnol 47(1):181–191
doi: 10.1080/21691401.2018.1548470
pubmed: 30686051
Ahangar P, et al (2018) Nanoporous 3D-printed scaffolds for local doxorubicin delivery in bone metastases secondary to prostate cancer. Materials (Basel) 11(9)
Phull SS et al (2021) Bone cement as a local chemotherapeutic drug delivery carrier in orthopedic oncology: a review. J Bone Oncol 26:100345
doi: 10.1016/j.jbo.2020.100345
pubmed: 33552885
Zhuang B et al (2020) Drug-loaded implantable surgical cavity-adaptive hydrogels for prevention of local tumor recurrence. Int J Pharm 577:119048
doi: 10.1016/j.ijpharm.2020.119048
pubmed: 31978462
Martin-Tellez KS, et al (2020) Isolated limb perfusion for soft tissue sarcoma: current practices and future directions. A survey of experts and a review of literature. Cancer Treat Rev 88: 102058
Lankelma J et al (1999) Doxorubicin gradients in human breast cancer. Clin Cancer Res 5(7):1703–1707
pubmed: 10430072
Ekstrom PO, et al (1997) Intratumoral differences in methotrexate levels within human osteosarcoma xenografts studied by microdialysis. Life Sci 61(19): Pl275–80
Achour B, Barber J, Rostami-Hodjegan A (2011) Cytochrome P450 Pig liver pie: determination of individual cytochrome P450 isoform contents in microsomes from two pig livers using liquid chromatography in conjunction with mass spectrometry [corrected]. Drug Metab Dispos 39(11):2130–2134
doi: 10.1124/dmd.111.040618
pubmed: 21795467